SLC5A2 and type 2 diabetes mellitus: <h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a novel class of oral antihyperglycemic medications prescribed for type 2 diabetes mellitus, play a beneficial role in slowing the progression of heart failure.